RxDoctor Payments DataLook up a doctor →

John Dolan, DO

Neurology · Portland, MENPI 1467416800

Payments from drug & device makers

$370,482in general payments, 2019–2025

Across 887 payments — averaging $417.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$163K
  • AbbVie$55K
  • Sanofi$35K
  • Amgen$32K
  • Acorda Therapeutics, Inc$29K
  • Neurocrine Biosciences, Inc.$20K
  • plus $36K from 24 others

What the payments were for

  • Consulting fees$11,1153%
  • Speaking & faculty fees$333,61990%
  • Travel & lodging$12,7763%
  • Food & beverage$12,6003%
  • Education$3720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$370,482 in reported general payments places this provider in the 90th percentile of 69 neurology providers in Maine.

See all neurology providers in Maine

Medicare billing

Part B allowed, 2024
$118,125
Medicare patients
275
Services billed
6,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5039$165,238
Nurtec OdtRimegepant Sulfate48$66,138
QuliptaAtogepant18$36,441
OngentysOpicapone36$31,096
UbrelvyUbrogepant15$24,832
Rasagiline Mesylate38$13,990
SavellaMilnacipran Hcl15$13,232
Rivastigmine55$11,261
Topiramate ErTopiramate14$10,718
Pregabalin137$8,587
Entacapone17$5,595
Memantine Hcl ErMemantine Hcl28$4,141
Duloxetine Hcl89$3,810
Gabapentin142$3,185
Oxcarbazepine21$2,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Savella$55,227$74,50548 claims
PfizerNurtec Odt$104$66,13848 claims
Neurocrine Biosciences, Inc.Ongentys$19,805$31,09636 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$154$78711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 neurology providers in Maine.

Other neurology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →